• Home
  • Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

  • Home
  • Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

  • Home
  • Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Participation in September Investor Conferences

  • Home
  • Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

  • Home
  • Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

  • Home
  • Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

  • Home
  • Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

  • Home
  • Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

  • Home
  • Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

  • Home
  • Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

  • Home
  • Anaptys Named a BioSpace 2024 Best Places to Work Winner

Anaptys Named a BioSpace 2024 Best Places to Work Winner

  • Home
  • Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

  • Home
  • Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

  • Home
  • AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors